Norah Alharbi1, Rawan Matar2, Edward Cupler3, Hindi Al-Hindi4, Hatem Murad5, Iftteah Alhomud5, Dorota Monies6, Ali Alshehri5, Mossaed Alyahya5, Brian Meyer6, Saeed Bohlega5. 1. Department of Clinical Science, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. 2. Salmaniya Medical Complex, Manama, Bahrain. 3. Department of Neuroscience, King Faisal Specialist Hospital, and Research Center, Jeddah, Saudi Arabia. 4. Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 5. Department of Neuroscience, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 6. Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Abstract
Background: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. Methods: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. Results: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. Conclusion: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended.
Background: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. Methods: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. Results: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. Conclusion: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended.
Authors: Karine Nguyen; Guillaume Bassez; Rafaëlle Bernard; Martin Krahn; Véronique Labelle; Dominique Figarella-Branger; Jean Pouget; El Hadi Hammouda; Christophe Béroud; Andoni Urtizberea; Bruno Eymard; France Leturcq; Nicolas Lévy Journal: Hum Mutat Date: 2005-08 Impact factor: 4.878
Authors: C Paradas; J Llauger; J Diaz-Manera; R Rojas-García; N De Luna; C Iturriaga; C Márquez; M Usón; K Hankiewicz; E Gallardo; I Illa Journal: Neurology Date: 2010-06-23 Impact factor: 9.910
Authors: J Andoni Urtizberea; Guillaume Bassez; France Leturcq; Karine Nguyen; Martin Krahn; Nicolas Levy Journal: Neurol India Date: 2008 Jul-Sep Impact factor: 2.117
Authors: Jordi Diaz-Manera; Roberto Fernandez-Torron; Jaume LLauger; Meredith K James; Anna Mayhew; Fiona E Smith; Ursula R Moore; Andrew M Blamire; Pierre G Carlier; Laura Rufibach; Plavi Mittal; Michelle Eagle; Marni Jacobs; Tim Hodgson; Dorothy Wallace; Louise Ward; Mark Smith; Roberto Stramare; Alessandro Rampado; Noriko Sato; Takeshi Tamaru; Bruce Harwick; Susana Rico Gala; Suna Turk; Eva M Coppenrath; Glenn Foster; David Bendahan; Yann Le Fur; Stanley T Fricke; Hansel Otero; Sheryl L Foster; Anthony Peduto; Anne Marie Sawyer; Heather Hilsden; Hanns Lochmuller; Ulrike Grieben; Simone Spuler; Carolina Tesi Rocha; John W Day; Kristi J Jones; Diana X Bharucha-Goebel; Emmanuelle Salort-Campana; Matthew Harms; Alan Pestronk; Sabine Krause; Olivia Schreiber-Katz; Maggie C Walter; Carmen Paradas; Jean-Yves Hogrel; Tanya Stojkovic; Shin'ichi Takeda; Madoka Mori-Yoshimura; Elena Bravver; Susan Sparks; Luca Bello; Claudio Semplicini; Elena Pegoraro; Jerry R Mendell; Kate Bushby; Volker Straub Journal: J Neurol Neurosurg Psychiatry Date: 2018-05-07 Impact factor: 10.154
Authors: Fiona L M Norwood; Chris Harling; Patrick F Chinnery; Michelle Eagle; Kate Bushby; Volker Straub Journal: Brain Date: 2009-09-18 Impact factor: 13.501